Benlysta® Belimumab 200 mg / mL Injection 4 per Box

Features

• BENLYSTA is a B-lymphocyte stimulator (BLyS)-specific inhibitor indicated for the treatment of: patients aged 5 years and older with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy
• BENLYSTA is a B-lymphocyte stimulator (BLyS)-specific inhibitor indicated for the treatment of: adult patients with active lupus nephritis who are receiving standard therapy.
• BENLYSTA (belimumab) injection is a clear to opalescent, and colorless to pale yellow solution for subcutaneous use. Each single-dose prefilled syringe is designed to deliver 200 mg of belimumab in 1 mL of solution and is supplied as follows: 200 mg/mL single-dose prefilled glass syringe with 27-gauge, half-inch needle attached in a carton of 4 (NDC 49401-088-47).
• Requires Refrigeration